Remove pharmaceutical-engineering march-april-2020 sustainability-life-sciences-industry-global
article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

Emerging digital health technologies (DHTs) may improve the quality of life for patients with chronic and debilitating diseases and provide novel health care solutions for patients with unmet medical needs. life-threatening disease or condition. Uses ML algorithms to make decisions and. predictions for a noncritical, nonserious, or.

article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

Cauchon, PhD 1 September 2023 The biopharmaceutical industry must develop and implement innovative ways of working to be effective and efficient in the current healthcare ecosystem, in which high-quality medicines, adaptability, and assurance of supply are of critical importance. McQueen Nina S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Challenges for Net Zero Carbon Pharmaceutical Manufacturing

ISPE

Challenges for Net Zero Carbon Pharmaceutical Manufacturing Trudy Patterson Mon, 03/06/2023 - 12:40 Features March / April 2023 Challenges for Net Zero Carbon Pharmaceutical Manufacturing Keith M. Sixth Assessment Report: Climate Change 2021: The Physical Science Basis.” C global warming scenario.

article thumbnail

Agile, Data-Driven Life Cycle Management for Continuous Manufacturing

ISPE

This article provides a review on the current state of CM implementation, offers insights into life cycle management and regulatory aspects, and explains how a data- and knowledge-centric approach to risk management can help CM achieve its full potential. This is demonstrated by the rise from $1.05 billion US in 2021 to $1.9

article thumbnail

A New Regulatory Approach to Drive Sustainable Medicines

ISPE

This article reviews two case studies that cover sustainable pack types and extension of shelf life. With the drive to manage unmet medical need through acceleration of drug development programs, postapproval sustainability variations will always be required. 1 Now there’s an additional focus: sustainability.